Kombinierte intravitreale Therapie zur Behandlung der altersbedingten Makuladegeneration

Zusammenfassung

Seit Einführung der intravitrealen Anti-VEGF-Monotherapie konnte bei einem signifikanten Teil der Patienten mit feuchter altersbedingter Makuladegeneration (AMD) der Visus stabilisiert bzw. verbessert werden. Es wird jedoch zunehmend über Sicherheit, Effektivität und ökonomische Aspekte der verschiedenen Konzepte therapeutischer Möglichkeiten diskutiert. Im Rahmen einer prospektiven Fallserie wurde 24 bis 36 Stunden nach initialer fotodynamischer Therapie bei 52 Patienten mit choroidealen Neovaskularisationen bei AMD eine intravitreale Kombinationstherapie durchgeführt. Dabei wurde eine intravitreale Eingabe von BSS, Dexamethason und Bevacizumab (= Multiple Therapie) ohne Parazentese mit dem Intrector® durch eine selbstadaptierende 23-Gauge-Kernvitrektomie ermöglicht, da dieser einen doppelläufigen Kanal für Aspiration und Injektion besitzt. Nach 14 Monaten zeigte sich durchschnittlich ein Visusgewinn von 0,18 Snellen Zeilen, mit einer Visusstabilisierung bei 14 / 52 (27 %) und einem Visusgewinn bei 38 / 52 (73 %) der Patienten. Dieses sichere pharmakochirurgische Therapiekonzept führte zu niedrigen intravitrealen Anti-VEGF-Wiederholungsraten 13 / 52 (25 %).

Abstract

Since the introduction of anti-VEGF drugs for the treatmet of CNV in age-related macular degeneration (AMD), visual acuity can be stabilised or improved in a significant number of patients. There is an ongoing debate on the safety, efficiency and economic aspects related to current intravitreal therapeutic concepts. Twenty-four to 36 hours after 80 % low-fluence verteporfin photodynamic therapy (PDT) a combined phrarmacosurgical intravitreal therapy for 52 patients with wet AMD was conducted (multiple therapy). By performing a 23-gauge core vitrectomy with the Intrector®, an intravitreal substitution with BSS, dexamethasone and bevacizumab was achieved via a self-adapting two-channel cannula for aspiration and injection in one probe tip. After 14 months the mean gain in visual acuity (VA) was 0.18 Snellen lines, with VA stabilisation in 14 / 52 (27 %) and VA gain in 38 / 52 (73 %) of the patients. This safe pharmacosurgical regimen indicated a low intravitreal retreatment rate of (13 / 52) 25 %.

Schlüsselwörter

AMD - Kombinationstherapie - Intrector - Anti-VEGF - Multiple Therapie

Key words

AMD - combined therapy - Intrector - anti-VEGF - multiple therapy

Literatur

• 1 Brown D M, Kaiser P K, Michels M. et al . Ranibizumab versus verteporfin for neovascular age-related macular degeneration.  N Engl J Med. 2006;  355 1432-1444
• 2 Gragoudas E S, Adamis A P, Cunningham E T. et al . Pegaptanib for neovascular age-related macular degeneration.  N Engl J Med. 2004;  351 2805-2816
• 3 Rosenfeld P J, Brown D M, Heier J S. et al . Ranibizumab for neovascular age-related macular degeneration.  N Engl J Med. 2006;  355 1419-1431
• 4 Spaide R F, Laud Jr. K, Fine H F. et al . Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.  Retina. 2006;  26 383-390
• 5 Chatterjee S P, DaCosta J, Adewoyin T. et al .Combined Photodynamic Therapy with Visudyne, Intravitreal Injection of Lucentis and Dexamethasone, and Oral Minocycline in the Treatment of Neovascular Age-Related Macular Degeneration. Ft. Lauderdale; Association of Research in Vision and Ophthalmology -ARVO 2008
• 6 Tolentino M J, Berger A, Misch D. et al .Decreased Retreatments and Maintained Efficacy With Triple Therapy (Combination Verteporfin Photodynamic Therapy, Intravitreal Avastin/Lucentis and Intravitreal Dexamethasone Teatments) for Patients with Exudative Age Related Macular Degeneration. Ft. Lauderdale; Association of Research in Vision and Ophthalmology – ARVO 2008
• 7 Grossniklaus H E, Ling J X, Wallace T M. et al . Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization.  Mol Vis. 2002;  8 119-126
• 8 Penfold P L, Liew S C, Madigan M C. et al . Modulation of major histocompatibility complex class II expression in retinas with age-related macular degeneration.  Invest Ophthalmol Vis Sci. 1997;  38 2125-2133
• 9 Penfold P L, Madigan M C, Gillies M C. et al . Immunological and aetiological aspects of macular degeneration.  Prog Retin Eye Res. 2001;  20 385-414
• 10 Dvorak H F, Nagy J A, Feng D. et al . Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis.  Curr Top Microbiol Immunol. 1999;  237 97-132
• 11 Espinosa-Heidmann D G, Reinoso M A, Pina Y. et al . Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization.  Exp Eye Res. 2005;  80 369-378
• 12 Grossniklaus H E, Green W R. Choroidal neovascularization.  Am J Ophthalmol. 2004;  137 496-503
• 13 Tsutsumi-Miyahara C, Sonoda K H, Egashira K. et al . The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation.  Br J Ophthalmol. 2004;  88 1217-1222
• 14 Pugh C W, Ratcliffe P J. Regulation of angiogenesis by hypoxia: role of the HIF system.  Nat Med. 2003;  9 677-684
• 15 Shweiki D, Itin A, Soffer D. et al . Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.  Nature. 1992;  359 843-845
• 16 Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C. et al . Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor.  Invest Ophthalmol Vis Sci. 2003;  44 4473-4480
• 17 Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.  Arch Ophthalmol. 1999;  117 1329-1345
• 18 Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy report 2.  Am J Ophthalmol. 2001;  131 541-560
• 19 Schmidt-Erfurth U M, Pruente C. Management of neovascular age-related macular degeneration.  Prog Retin Eye Res. 2007;  26 437-451
• 20 Chen C Y, Wong T Y, Heriot W J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.  Am J Ophthalmol. 2007;  143 510-512
• 21 D’Amico D J, Masonson H N, Patel M. et al . Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.  Ophthalmology. 2006;  113 992-1001 e1006
• 22 Mieler W. PIER: 1 Year FA/OCT Results in a Study of Ranibizumab (Lucentis®) for Choroidal Neovascularisation (CNV) due to Age related Macular Degeneration (AMD). 24th Annual meeting of the American Society of Retina Specialists and 6th annual meeting of the European Vitreoretinal Society Cannes, France; 2006
• 23 Fung A E, Lalwani G A, Rosenfeld P J. et al . An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.  Am J Ophthalmol. 2007;  143 566-583
• 24 Danis R P, Ciulla T A, Pratt L M. et al . Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.  Retina. 2000;  20 244-250
• 25 Gillies M C, Simpson J M, Billson F A. et al . Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial.  Arch Ophthalmol. 2004;  122 336-340
• 26 Jonas J B, Akkoyun I, Budde W M. et al . Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration.  Arch Ophthalmol. 2004;  122 218-222
• 27 Lee J, Freeman W R, Azen S P. et al . Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results.  Retina. 2007;  27 1205-1213
• 28 Augustin A J, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.  Ophthalmology. 2006;  113 14-22
• 29 Ruiz-Moreno J M, Montero J A, Barile S. et al . Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome.  Retina. 2006;  26 602-612
• 30 Spaide R F, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.  Ophthalmology. 2005;  112 301-304
• 31 Tatar O, Adam A, Shinoda K. et al . Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy.  Am J Ophthalmol. 2006;  142 95-104
• 32 Heier J S, Boyer D S, Ciulla T A. et al . Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.  Arch Ophthalmol. 2006;  124 1532-1542
• 33 Costa R A, Jorge R, Calucci D. et al . Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).  Graefes Arch Clin Exp Ophthalmol. 2007;  245 1273-1280
• 34 Dhalla M S, Shah G K, Blinder K J. et al . Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.  Retina. 2006;  26 988-993
• 35 Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.  Ophthalmology. 2007;  114 1179-1185
• 36 Augustin A J, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.  Retina. 2007;  27 133-140
• 37 Liggett P E, Colina J, Chaudhry N A. et al . Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization.  Am J Ophthalmol. 2006;  142 1072-1074
• 38 Ahmadieh H, Taei R, Soheilian M. et al . Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.  BMC Ophthalmol. 2007;  7 10
• 39 Aiello L P, Avery R L, Arrigg P G. et al . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.  N Engl J Med. 1994;  331 1480-1487
• 40 Ahmed J, Braun R D, Dunn R . et al . Oxygen distribution in the macaque retina.  Invest Ophthalmol Vis Sci. 1993;  34 516-521
• 41 Holekamp N M, Shui Y B, Beebe Jr. D. Vitreous consumes oxygen: implications for vitrectomy surgery. Aspen Vitrectomy meeting 2006
• 42 Stefansson E, Landers 3 rd M B. How does vitrectomy affect diabetic macular edema?.  Am J Ophthalmol. 2006;  141 984-985
• 43 Stefansson E, Loftsson T. The Stokes-Einstein equation and the physiological effects of vitreous surgery.  Acta Ophthalmol Scand. 2006;  84 718-719
• 44 Saito Y, Lewis J M, Park I. et al . Nonvitrectomizing vitreous surgery: a strategy to prevent postoperative nuclear sclerosis.  Ophthalmology. 1999;  106 1541-1545
• 45 Sawa M, Saito Y, Hayashi A. et al . Assessment of nuclear sclerosis after nonvitrectomizing vitreous surgery.  Am J Ophthalmol. 2001;  132 356-362
• 46 Holekamp N M. How the Vitreous consumes oxygen. Retina Subspecialty Day of the Annual American Academy of Ophthalmology New Orleans; 2007
• 47 Krebs I, Brannath W, Glittenberg C. et al . Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration?.  Am J Ophthalmol. 2007;  144 741-746